Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of <i>NTRK1</i>Matthew L. Hemming, Sandro Santagata, Michael J. Nathenson et al.|JCO Precision Oncology|2020Cited by 36
Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological CorrelatesCandace L. Haddox, Suzanne George, Priscilla Merriam et al.|Clinical Cancer Research|2024Cited by 35
Molecular characterization and management of secondary resistance to serial TRK inhibitors.Michael J. Nathenson, George D. Demetri, Karan Malik et al.|Journal of Clinical Oncology|2019Cited by 1
Data from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological CorrelatesCandace L. Haddox, Suzanne George, Michael J. Nathenson et al.|Unknown|2024Cited by 1
Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological CorrelatesCandace L. Haddox, Suzanne George, Michael J. Nathenson et al.|Unknown|2024Cited by 1